The foundation of the company was built upon academic research and the desire to develop deferiprone, an "orphan drug" that addresses unmet medical needs for people with the rare genetic blood disorder thalassemia. Evolving out of the Innovative Drug Division of Apotex Inc., ApoPharma achieved early research successes that led to its incorporation as a separate pharmaceutical company in 2004.
Our company is now reaping the benefits of years of scientific and financial investment, focusing on certain disorders in the fields of hematology and neurodegeneration in which treatments are inadequate or non-existent. A motivating force for all of us has been the achievement of some encouraging findings that we believe hold promise for patients with neurodegenerative conditions such as pantothenate kinase-associated neurodegeneration, Parkinson's disease, and other disorders where iron may play a critical role.
Michael Spino, Pharm.D.
We are proud that our commitment to research, development, and marketing of innovative pharmaceutical products continues to help people achieve improved health outcomes. Our key leaders bring decades of commitment, experience and accomplishment to our dedicated teams.